HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hemogenyx Pharmaceuticals has received IRB approval to begin a Phase I clinical trial of its lead therapy, HEMO-CAR-T, aimed at treating relapsed/refractory acute myeloid leukemia. This marks a significant step for the company in advancing a potentially groundbreaking treatment for a type of cancer with limited options. Investors may find this development promising as it could impact treatment and survival rates for AML.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
